Nurix Therapeutics (NRIX)

• Market cap: $1.4B
• 1 day: -0.20%
• 5 days: -4.07%
• 1 month: -9.30%
• 3 months: -17.88%
• 6 months: -5.90%
• Year to date: 93.64%
• 1 year: 104.44%
• 5 years: 4.10%
• 10 years: 4.10%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.

Employees: 284

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

52% more call options, than puts

Call options by funds: $1.84M | Put options by funds: $1.21M

14% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 57

9% more capital invested

Capital invested by funds: $1.4B [Q2] → $1.52B (+$120M) [Q3]

6% less first-time investments, than exits

New positions opened: 29 | Existing positions closed: 31

1% less funds holding

Funds holding: 173 [Q2] → 171 (-2) [Q3]

8.03% less ownership

Funds ownership: 112.93% [Q2] → 104.9% (-8.03%) [Q3]

25% less funds holding in top 10

Funds holding in top 10: 4 [Q2] → 3 (-1) [Q3]

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $26 31% upside
• Avg. target: $33 69% upside
• High target: $41 107% upside

8 analyst ratings

• positive: 8 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Robert Burns 23% 1-year accuracy 36 / 155 met price target	77% upside $35	Buy Maintained	11 Dec 2024
BTIG Jeet Mukherjee 0% 1-year accuracy 0 / 2 met price target	77% upside $35	Buy Initiated	10 Dec 2024
Needham Gil Blum 21% 1-year accuracy 34 / 164 met price target	47% upside $29	Buy Reiterated	10 Dec 2024
BMO Capital Etzer Darout 29% 1-year accuracy 12 / 41 met price target	77% upside $35	Outperform Initiated	6 Dec 2024
UBS David Dai 18% 1-year accuracy 2 / 11 met price target	77% upside $35	Buy Initiated	24 Oct 2024